CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 11 No. 1
Pages: 1  2  
Next
 

Concurrent Chemo/Radiotherapy in Oropharynx Cancer

January 1, 2002

SAN FRANCISCO—Chemotherapy given concomitantly with radiotherapy improves disease-free survival rates in patients with stages III and IV oropharynx carcinoma, according to final results of the 94-01 GORTEC study. The findings were presented at the 43rd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO plenary 2).

After a median follow-up of 63 months, the 5-year disease-free survival rate was 30% for patients who received chemotherapy plus radiotherapy vs 15% for those who received radiotherapy only (P = .025). The increase in survival rates, however, was accompanied by an increased incidence of grade 3-4 toxicity.

"Adding chemotherapy to radiation therapy does improve local control and does improve disease-free survival," said Jean Bourhis, MD, of the Institut Gustave-Roussy, Villejuif, France. "However, there is a price because both acute and late toxicity were enhanced."

Dr. Bourhis presented the results on behalf of Dr. Gilles Calais, of the Department of Radiation Oncology, Hôpital Bretonneau, Tours, France, who was not able to attend the ASTRO meeting. Dr. Calais is the lead author of the study.

Between July 1994 and September 1997, this phase III multicenter study enrolled 226 European patients with locally advanced stage III/IV oropharynx carcinoma. Patients received radiation therapy only (70 Gy in 35 fractions) or radiation therapy plus three cycles of a 4-day course of carboplatin(Drug information on carboplatin) (Paraplatin) 70 mg/m²/d and fluorouracil(Drug information on fluorouracil) 500 mg/m²/d, given on days 1, 22, and 43.

The two arms were balanced for patient age, sex, stage, performance status, histology, and primary tumor site. The most common tumor sites were the tonsils and the base of the tongue.

Although it improved survival, chemoradiotherapy also resulted in an increased incidence of acute and late toxicity. The rate of grade 3-4 mucositis was 67% in patients treated with concomitant chemoradiation vs 36% for those who received radiation therapy only. There was one toxicity-related death in the combination arm.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy